Objectives: 1) Supervision of the scientific progress towards the network's planned objectives; 2) Day-to-day financial and administrative management including secondments, reports, communication between partners and the EC; 3) Logistical support and follow-up of consortium meetings and related activities; 4) Communication and dissemination of project knowledge and results; 6) Supporting exploitation of results by partners towards their networks and beyond; 7)Promotion of gender balance in the consortium’s research teams.

Objectives: 1) Planning and coordination of network-wide training events; 2) Planning and coordination of local training events; 3) Planning and coordination of webinars; 4) Planning and coordination of individual and shared secondments.

Objectives 1)Acquisition and proteomic analysis of EVs from patients with BC, LC and HC and from healthy donors; 2)Acquisition and proteomic analysis of EVs produced by normal or immortalized breast, and liver cell lines; 3) Acquisition and proteomic analysis of EVs produced by cell lines of BC, HC, and LC to select the cell lines that best fit pathological phenotype in patients; 4) Acquisition and analysis of plant EVs from various edible sources such as ginger, grape, lemon, grapefruit etc to select the source with compromised in vitro immunogenicity

Objectives: Selection, and validation of the Nbs for EV purification unit

Objectives: 1) Development of novel EVs purification system based on NbS and solid carrier; 2) Validation of developed unit on different biological samples; 3) Optimising protocols for system application in large-scale EVs production 4) Optimising protocols for system application in high-throughput EVs isolation.

Objectives: 1) Validation of the PROTOTYPE purification system for EVs based stratification of BC, LC and HC management

Objectives 1)Validation of the PROTOTYPE purification system for isolation of PDEVs; 2) Development of efficient drug loading strategy to PDEVs; 3) Determination of the in vitro effect of drug-loaded PDEVs on the selected BC, HC and LC, by monitoring cell viability 4) Determination of the in vivo effect of drug-loaded PDEVs on orthotopic BC xenograft model.